Clinical Trial to Assess Bioequivalence of Lazertinib Between Two Formulations in Healthy Volunteers.

Inclusion Criteria

• •Male, over 19 years of age
• •Male participants must agree to use an adequate contraception method from the first to the third month after the last dose.
• •Participants must have a body mass index (BMI) between 18.5 and 30.0 kg/m2, inclusive(BMI = weight/height2), and body weight not less than 50 kg.
• •Subjects without congenital or chronic diseases within the last 3 years and without pathologic symptoms as determined by medical diagnosis.
• •Participants must be healthy on the basis of clinical laboratory tests performed at screening.
• •Informed of the investigational nature of this study and voluntarily agree to participate in this study.